What is the appropriate intranasal midazolam (Versed) dose for a 7‑year‑old child (approximately 20–25 kg) undergoing laceration repair?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intranasal Midazolam Dosing for 7-Year-Old Laceration Repair

For a 7-year-old child undergoing laceration repair, administer 0.4 to 0.5 mg/kg of intranasal midazolam (maximum 10 mg), with the procedure ideally performed 10-15 minutes after administration.

Recommended Dosing Protocol

The optimal dose range is 0.4-0.5 mg/kg intranasal 1. Recent high-quality evidence demonstrates that:

  • 0.4 mg/kg and 0.5 mg/kg are equally effective and superior to lower doses 1
  • Doses of 0.2-0.3 mg/kg have significantly higher failure rates (only 27% adequate sedation at 0.2-0.29 mg/kg vs 100% at 0.4-0.5 mg/kg) 2
  • High-dose intranasal midazolam (0.5 mg/kg) requires fewer rescue sedatives compared to low-dose (0.2 mg/kg): 7.4% vs 28% needed additional medications 3

For a typical 7-year-old weighing 20-25 kg, this translates to 8-12.5 mg total dose.

Timing and Administration

Peak plasma concentration occurs at approximately 10 minutes after intranasal administration 4. The optimal procedural window is:

  • 5-17 minutes post-administration when plasma levels are >90% of maximum 4
  • Onset of minimal sedation: 4-5 minutes 5
  • Plan to start the procedure at 10-15 minutes for optimal effect

Volume of Administration

Use 0.5 mL volume for administration 5. While 0.2 mL, 0.5 mL, and 1 mL volumes all produce comparable sedation times, clinicians report lower satisfaction with 0.2 mL due to difficulty of administration 5.

Safety Profile

Intranasal midazolam at these doses is remarkably safe:

  • No serious adverse events reported in recent trials 1
  • Adverse event rate: 1.6% vomiting, 1.6% paradoxical reaction 4
  • No clinically significant oxygen desaturation in multiple studies 2
  • Successful procedure completion in 97% of patients 4

Critical Safety Considerations

Be prepared for respiratory support regardless of route 6. Essential monitoring includes:

  • Continuous pulse oximetry 7
  • Have flumazenil 0.01 mg/kg immediately available for reversal 6
  • Monitor for at least 41 minutes (mean recovery time) 2
  • Paradoxical agitation may occur, especially in younger children 6

Common Pitfall to Avoid

Do not underdose. The most common error is using 0.2 mg/kg based on older guidelines for IV sedation 6. Intranasal administration requires higher doses than IV due to different pharmacokinetics. Using 0.2 mg/kg intranasally results in a 73% failure rate requiring rescue sedation 3.

Alternative Considerations

If combining with local anesthesia, the sedation requirements may be reduced, but topical or injected local anesthesia was used in 93% of successful cases in the original intranasal midazolam studies 2. The midazolam provides anxiolysis and amnesia while local anesthesia provides pain control.

For children <6 years old, oral midazolam 0.5 mg/kg (maximum 20 mg) is an alternative 6, though intranasal has faster onset and more predictable absorption.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.